What is it about?
Diabetes is considered a risk factor for developing heart problems, including blocked arteries in the heart (called coronary artery disease, or CAD). Many research studies have been conducted to understand why this happens and how we can predict which patients are most at risk of complications. In this study, we studied a protein in the blood called suPAR, which is proven to be marker of inflammation and poor health outcomes. We found that suPAR levels were higher in people with diabetes, and these high levels were associated with worse outcomes in those with heart disease. Our research suggests that suPAR might help explain why diabetes leads to more serious heart problems. This means that testing suPAR levels could help doctors identify patients at higher risk and offer them more targeted care
Featured Image
Why is it important?
People with diabetes are known to have worse outcomes from heart disease, but this study suggests that the risk is not explained by diabetes alone. Higher levels of a blood marker called suPAR were associated with a greater risk of death in patients with coronary artery disease, regardless of whether they had diabetes. These findings indicate that suPAR may help refine risk assessment, particularly among patients with diabetes, and could support more targeted follow-up in the future.
Perspectives
I was interested in this question because diabetes is often treated as a single explanation for worse outcomes in coronary artery disease, even though patient risk varies widely. In this work, I view suPAR not as a replacement for established risk factors, but as a marker that may better reflect underlying biological stress and chronic inflammation that diabetes alone does not fully capture. While these findings are observational and require further validation, they support a more nuanced view of risk in coronary artery disease. More broadly, I believe this study contributes to an emerging inflammation-centered perspective, suggesting that inflammation may represent a disease process in its own right—one that should be tracked and, potentially, targeted through future interventions.
Shaimaa Sakr
Emory University
Read the Original
This page is a summary of: Soluble Urokinase Plasminogen Activator Receptor (suPAR) Mediates the Impact of Diabetes on Adverse Outcomes in Coronary Artery Disease, Diabetes Care, January 2026, American Diabetes Association,
DOI: 10.2337/dc25-0940.
You can read the full text:
Contributors
The following have contributed to this page
